anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After hemorrhage control, pulp chamber was cleansed with physiologic saline prior the MTA pulpotomy. Then, canal orifices were sealed with MTA (ProRoot MTA; Dentsply, Tulsa, OK, USA) and a moistened cotton pellet was placed over the MTA paste to allow setting of the material. Reinforced ZOE was placed as a temporary restoration; the ZOE and the cotton pellets were removed after 24 h, and the teeth finally restored with SSCs.
Dysregulation of cholesterol metabolism is an important feature of cancer development. There are limited reports on the involvement of lncRNAs in hepatocellular carcinoma (HCC) progression via the cholesterol metabolism pathway. The present study explored the effect of LINC00618 on HCC growth and metastasis, and elucidated the underlying mechanisms involved in cholesterol metabolism. Here, we found that LINC00618 expression was upregulated in cancerous tissues from 30 patients with HCC compared to that in adjacent normal tissues. High expression of LINC00618 was detected in metastatic HCC tissues. LINC00618 is predominantly localized in the nucleus and overexpression of LINC00618 facilitated HCC cell proliferation, migration and EMT progression by promoting cholesterol biosynthesis. Mechanistically, the 1-101nt region of LINC00618 bound to NSUN2. LINC00618 inhibited ubiquitin-proteasome pathway-induced NSUN2 degradation. NSUN2 stabilized by LINC00618 increased m5C modification of SREBP2 and promoted SREBP2 mRNA stability in a YBX1-dependent manner, thereby promoting cholesterol biosynthesis in HCC cells. Moreover, mouse HCC xenograft and lung metastasis models were established by subcutaneous and tail vein injections of MHCC97 cells transfected with or without sh-LINC00618. Silencing LINC00618 impeded HCC growth and metastasis. In conclusion, LINC00618 promoted HCC growth and metastasis by elevating cholesterol synthesis by stabilizing NSUN2 to enhance SREBP2 mRNA stability in an m5C-dependent manner.
All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
The participant will arrive fasted at Diex Recherche Sherbrooke. After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment. The choice of the treatment/comparator will be random. In this arm, the participant will receive the omega-3 fatty acids as a unique dose of 3 g EPA + DHA in monoacylglycerol form + 45 mg vitamin K2. The participant will consume this unique dose with a standardized breakfast. There will thereafter be blood sample collection over 24 h to evaluate the level of omega-3 fatty acids in the plasma.
FIELD: phytopharmacy. SUBSTANCE: invention relates to preparing drugs from plants. Method involves milling above-ground part of flowering plant, its exposition up to formation of dry fermentation liquid products. Then mixture is poured with drinking water and infusion is kept up to the end of fermentation followed by filtration of product formed. At the stage of formation of liquid products of dry fermentation milled plant is subjected for a single or repeated spraying with the same early prepared drug. After termination of formation of dry fermentation liquid products the latter are poured with drinking water and kept up to the end of fermentation. Liquid fraction is filtered off. EFFECT: increased stability and pharmacological activity of product. 13 cl, 1 tbl
The present invention relates to a medium composition for culturing fibroblast, a method for culturing fibroblast using the medium, and a skin regeneration composition comprising the cultured fibroblast. More specifically, the present invention relates to a method for culturing fibroblast, which comprises the following steps: preparing fibroblast; culturing fibroblast on a culture plate coated with an extracellular matrix by using a culture fluid comprising a serum substitute; and separating the cultured fibroblast. The present invention further relates to a skin regeneration composition using the same. The medium composition for culturing fibroblast and the method for culturing fibroblast using the same can promote proliferation of cells and inhibits cell aging without uses of the serum. In addition, culturing fibroblast which retains normal cell conformation even for a long period of culturing time is also possible as well. The fibroblast cultured thereby can be useful as the skin regeneration composition and a skin anti-aging composition.
Techniques for programming electrical stimulation therapy intensity based on electrical charge are described. In some examples, a display presents a stimulation intensity value in units of electrical charge, e.g., Coulombs. In such examples, a user may adjust the displayed charge value, rather than pulse amplitude or pulse width, to adjust the intensity of the electrical stimulation therapy. In some examples, a processor determines modifications to pulse amplitude and pulse width based on the modification to the charge value. In some examples, a processor modifies a pulse amplitude and width to achieve a desired charge, while maintaining a relationship between pulse amplitude and width specified by a predetermined function. In some examples, the function may be programmed, e.g., selected or adjusted, by a user.
PURPOSE: A pharmaceutical composition containing turtle extract is provided to improve immunity. CONSTITUTION: A pharmaceutical composition for preventing or treating dermatitis contains 0.1-20 wt% of turtle extract as an active ingredient. The extract is prepared by hot water at 80-100°C. The extract is also prepared using alcohol or alcohol solution. The dermatitis includes atopic dermatitis, acne, athlete's foot, psoriasis, and eczema. The pharmaceutical composition is manufactured in the form of a tablet, pill, granule, soft/hard capsule, powder, emulsion, and syrup.
A callikrein inactivator free from antigens and pyrogens is obtained by extracting comminuted animal organs containing the callicrein inactivator (i.e. lymphatic and parotid glands liver, spleen pancreas and lung) with an aqueous solution of a salt or hydroxide of an alkaline earth metal or of an alkali metal, ammonium or magnesium. Typical salts are calcium chloride, magnesium chloride, strontium chloride, barium chloride, calcium hydroxide, sodium chloride and ammonium sulphate.  Preferably, the aqueous extract solution contains a water-miscible organic solvent such as methanol, ethanol, propanol and dioxane.  The extract is treated with a ketone, e.g. acetone in the presence of a finely divided inert carrier, e.g. kieselguhr to preceipitate the active material which is dried and extracted with water.  Proteins are precipitated from the aqueous extract by the addition of a protein precipitant especially sulphosalicylic acid and excess precipitant is removed from the clarified solution by the addition of ion exchangers batchwise, e.g. cation exchange resin in H+ form, e.g. Amberlite IR-120, followed by anion exchange resin on (OH) cycle, e.g. "Amberlite IRA-400" (Registered Trade Mark).  The residual solution is filled into ampoules aseptically. Specification 783,316 is referred to.
FIELD: confectionery industry. SUBSTANCE: method involves feeding substance and/or product to be treated into cylinder rotating at speed not exceeding 40 rev/min and provided with at least one spiral brush positioned in parallel with cylinder axis. Brush is in contact, through at least one of its generatrices, with at least one generatrix of lower part of cylinder inner wall, so that it is rotated at speed not exceeding 100 rev/min in the direction opposite to that of cylinder. Machine has horizontal or inclined cylinder with charging and discharge ends, cylinder drive, at least one spiral brush positioned within cylinder and provided with drive. Brush is positioned for rotation in the direction opposite to that of cylinder in parallel with cylinder axis. Brush is in contact, through at least one of its generatrices, with at least one generatrix of lower part of cylinder inner wall. EFFECT: increased efficiency and improved quality of product. 18 cl, 9 dwg
Autism spectrum disorder (ASD) is associated with multiple physiological abnormalities. Current laboratory and clinical evidence most commonly report mitochondrial dysfunction, oxidative stress, and immunological imbalance in almost every cell type of the body. The present work aims to evaluate oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and inflammation-related molecules such as Cyclooxygenase-2 (COX-2), chitinase 3-like protein 1 (YKL-40), Interleukin-1 beta (IL-1β), Interleukin-9 (IL-9) in ASD children with and without regression compared to healthy controls. Children with ASD (n = 56) and typically developing children (TDC, n = 12) aged 1.11 to 11 years were studied. Mitochondrial activity was examined in peripheral blood mononuclear cells (PBMCs) isolated from children with ASD and from the control group, using a metabolic analyzer. Gene and protein levels of IL-1β, IL-9, COX-2, and YKL-40 were investigated in parallel. Our results showed that PBMCs of the ASD subgroup of regressed patients (ASD R(+), n = 21) had a specific pattern of mitochondrial activity with significantly increased maximal respiration, respiratory spare capacity, and proton leak compared to the non-regressed group (ASD R(-), n = 35) and TDC. Furthermore, we found an imbalance in the studied proinflammatory molecules and increased levels in ASD R(-) proving the involvement of inflammatory changes. The results of this study provide new evidence for specific bioenergetic profiles of immune cells and elevated inflammation-related molecules in ASD. For the first time, data on a unique metabolic profile in ASD R(+) and its comparison with a random group of children of similar age and sex are provided. Our data show that mitochondrial dysfunction is more significant in ASD R(+), while in ASD R(-) inflammation is more pronounced. Probably, in the group without regression, immune mechanisms (immune dysregulation, leading to inflammation) begin initially, and at a later stage mitochondrial activity is also affected under exogenous factors. On the other hand, in the regressed group, the initial damage is in the mitochondria, and perhaps at a later stage immune dysfunction is involved.
The present invention disclosed a pharmaceutical preparation of Chinese herb which consists of Kidney-reinforcing and antiasthma herbs, wherein said Chinese herbs comprises Ferilla Frutescens, Prunus Armeniaca, Glycyrrhiza Uralensis, Scutellaria Baicalensis, Coptis Chinesis, Tusilago Farfara, Stemona Sessilifolia, Fritllaria Cirrhosa, Pheretima Aspergillum, Psoralea Corylifolia, Codonopsis Pilosula, Hordeum Vulgara, Massa Fermentata Medicalis, Schisandra Chinensis, Gypsum. The preparation has been used in China for 20 years, and in Israel for more than 5 years. It has cured thousands of patients suffering from asthma, with the effective rate of 93%. The present pharmaceutical preparation can relieve cough, expel phlegm, resist the airway allergic inflammation reaction, improve the pulmonary function and the partial pressure of the oxygen in blood, increase CD2, CD4, CD4/CD8, reduce IgE in blood, and increase CAMP, reduce CGMP in blood, stabilize clasmatoblasts, inhibit the release of histamine, stop asthmatic attack. As is shown in the electron microscope, the preparation protects pneumonocytes, increase the pneumonocytes of type 2, and recover the vital capacity. It can be applied to hormone depending patients for adjusting the decrease of the cerebral ganglia   hypophysis   adrenal axes. To further demonstrate the curative effect, a study of clinical observation was carried out in the Tel-Hashomer Hospital in Israel, which proved the effect was quit remarkable.
PURPOSE: The purpose of this study was to describe the clinical features, management, outcomes, and diagnostic pitfalls in a large series of patients with ocular neuromyotonia.
DESIGN: Retrospective cohort.
METHODS: Patients diagnosed with ocular neuromyotonia from January 1, 2004, through January 1, 2023, seen at one of the 3 Mayo Clinic sites in Rochester, MN, Scottsdale, AZ, and Jacksonville, FL, comprised the study population. We ascertained patients with ocular neuromyotonia through a search using the medical records database. Only patients with an observed episode of ocular neuromyotonia were included and the medical records were reviewed. The main outcome measures were clinical features and outcomes of patients with ocular neuromyotonia.
RESULTS: Forty-two patients who were diagnosed with ocular neuromyotonia were included. The median age was 58 years (range, 16-80 years). A history of cranial radiation therapy was present in 39 patients (93%). The sixth cranial nerve was involved in 31 patients (74%). Bilateral disease was found in 2 patients (5%). The median time from onset of diplopia to diagnosis was 8 months (range, 1 month-25 years), with a high rate of initial misdiagnosis in 52%. Twenty of 42 patients (48%) were treated with oral medication, of whom 95% had significant improvement or resolution of symptoms.
CONCLUSION: Prior cranial irradiation is the most common cause for ocular neuromyotonia, affecting the sixth cranial nerve most often. Although delayed and initial misdiagnosis is common, most patients show improved symptoms on medical treatment.
INTRODUCTION: Guillain-Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as triggers of autoimmune responses leading to neural damage and dysfunction.
AREAS COVERED: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.
EXPERT OPINION: The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.
PURPOSE:To provide the titled food containing dried powder and/or extract of SOKUZU (Sumbucus chinensis) as an essential component. CONSTITUTION:The whole parts of the whole grass of SOKUZU (a perennial plant of Caprifoliaceae family) or the overground part excluding the root are dried spontaneously, and finely pulverized. After removing the impurities by simply washing with water, the product is freeze-dried to obtain powder. The powder is heated and extracted with a lower aliphatic alcohol such as methanol, etc., or water under distillation to obtain a concentrated extract, which is used as an essential component of the objective food effective to mitigate the tenosynovitis. The remedying effect can be further improved by adding the dry powder and/or extract of the leaf of carrot compared with the single use of SOKUZU. The daily dose of SOKUZU is 100-10,000mg, preferably 200-500mg in terms of the extract. It can be administered in the form of pill, granule, powder, refreshing drink, etc., especially as a tea.
OBJECTIVES: We hypothesized that emergency complications related to asymptomatic paraconduit hernias may occur less often than generally believed. Therefore, we assessed the occurrence and timing of paraconduit hernia diagnosis after esophagectomy, as well as outcomes of these asymptomatic patients managed with a watch-and-wait approach.
METHODS: From 2006 to 2021, 1214 patients underwent esophagectomy with reconstruction at the Cleveland Clinic. Among these patients, computed tomography scans were reviewed to identify paraconduit hernias. Medical records were reviewed for timing of hernia diagnosis, hernia characteristics, and patient symptoms, complications, and management. During this period, patients with asymptomatic paraconduit hernias were typically managed nonoperatively.
RESULTS: Paraconduit hernias were identified in 37 patients. Of these, 31 (84%) had a pre-esophagectomy hiatal hernia. Twenty-one hernias (57%) contained colon, 7 hernias (19%) contained pancreas, and 9 hernias (24%) contained multiple organs. Estimated prevalence of paraconduit hernia was 3.3% at 3 years and 7.7% at 10 years. Seven patients (19%) had symptoms, 4 of whom were repaired electively, with 2 currently awaiting repairs. No patient with a paraconduit hernia experienced an acute complication that required emergency intervention.
CONCLUSIONS: The risk of paraconduit hernia increases with time, suggesting that long-term symptom surveillance is reasonable. Emergency complications as a result of asymptomatic paraconduit hernias are rare. A small number of patients will experience hernia-related symptoms, sometimes years after hernia diagnosis. Our findings suggest that observation of asymptomatic paraconduit hernias (watch and wait) may be considered, with repair considered electively in patients with persistent symptoms.
BACKGROUND: Anoikis resistance is a hallmark characteristic of oncogenic transformation, which is crucial for tumor progression and metastasis. The aim of this study was to identify and validate a novel anoikis-related prognostic model for prostate cancer (PCa).
METHODS: We collected a gene expression profile, single nucleotide polymorphism mutation and copy number variation (CNV) data of 495 PCa patients from the TCGA database and 140 PCa samples from the MSKCC dataset. We extracted 434 anoikis-related genes and unsupervised consensus cluster analysis was used to identify molecular subtypes. The immune infiltration, molecular function, and genome alteration of subtypes were evaluated. A risk signature was developed using Cox regression analysis and validated with the MSKCC dataset. We also identify potential drugs for high-risk group patients.
RESULTS: Two subtypes were identified. C1 exhibited a higher level of CNV amplification, immune score, stromal score, aneuploidy score, homologous recombination deficiency, intratumor heterogeneity, single-nucleotide variant neoantigens, and tumor mutational burden compared to C2. C2 showed a better survival outcome and had a high level of gamma delta T cell and activated B cell infiltration. The risk signature consisting of four genes (HELLS, ZWINT, ABCC5, and TPSB2) was developed (area under the curve = 0.780) and was found to be an independent prognostic factor for overall survival in PCa patients. Four CTRP-derived and four PRISM-derived compounds were identified for high-risk patients.
CONCLUSIONS: The anoikis-related prognostic model developed in this study could be a useful tool for clinical decision-making. This study may provide a new perspective for the treatment of anoikis-related PCa.
The invention concerns human hexapetaloid duplicon 20 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammation utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes human hexapetaloid duplicon 20.
IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis worldwide and leads to end-stage kidney disease. The proteinuria selectivity index (PSI) has been used to assess the prognosis in nephrotic syndrome, but its predictive value in patients with IgAN remains unclear. This single-center retrospective cohort study included patients who diagnosed with IgAN between March 2012 and March 2020. The PSI was calculated at the time of kidney biopsy. Patients were followed up from the time of kidney biopsy to kidney replacement therapy, death, transfer to another facility, or study completion. Ninety-four patients with a median age of 51 years were enrolled and divided according to the cutoff value of PSI determined by the receiver operating characteristic curve analysis into low-PSI (PSI <0.243, n = 39) and high-PSI groups (PSI ≥0.243, n = 55). The median follow-up duration was 70 months. Rates of remission of proteinuria and survival without a two-fold increase in serum creatinine were significantly better in the low-PSI group (both p < 0.01, log-rank test). Cox regression analysis showed that a low PSI was significantly associated with an increased likelihood of remission of proteinuria and hematuria (hazard ratio [HR] 1.96; 95% confidence interval [CI] 1.02-3.85 and HR 1.75; 95% CI 1.01-3.13, respectively), and a decreased risk of a two-fold increase in serum creatinine (HR 0.10; 95% CI 0.01-0.81). In conclusion, The PSI could have the potential to support the assessment of the prognosis of IgAN, in addition to established prognostic markers, by reflecting the overall glomerular permeability.
Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
Randomization will allocate women to intervention and control arm in 1:1 ratio; with 6 wards in each group. The intervention arm will consist of 153 women who will receive "Cervical Cancer Stigma Reduction Intervention".
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment, in this case stereotactic radiation, to learn whether this treatment works in treating a specific disease. "Investigational" means that the treatment is being studied.

In patients with a limited number of brain metastases (spread of a cancer that started outside of the brain to the brain itself) the standard radiation option is stereotactic radiation, which involves using a high dose of radiation that only targets the specific metastases that are visible on imaging of the brain, not the whole brain itself. However, studies evaluating the role of stereotactic radiation to treat brain metastases generally excluded patients with small cell lung cancer. Therefore, among patients with small cell lung cancer and brain metastases, the typical treatment that has been offered is whole brain radiation. However, whole brain radiation has deleterious associated side effects including significant fatigue and permanent memory/attention problems. The investigators are studying whether stereotactic radiation can be effectively utilized for patients with small cell lung cancer and brain metastases in order to avoid such side effects.